nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—LTK—tongue—pharynx cancer	0.0176	0.0311	CbGeAlD
Ruxolitinib—LTK—mouth—pharynx cancer	0.0118	0.0209	CbGeAlD
Ruxolitinib—RPS6KA6—brainstem—pharynx cancer	0.00957	0.017	CbGeAlD
Ruxolitinib—JAK1—neck—pharynx cancer	0.00802	0.0142	CbGeAlD
Ruxolitinib—GRK7—head—pharynx cancer	0.00778	0.0138	CbGeAlD
Ruxolitinib—ANKK1—head—pharynx cancer	0.00711	0.0126	CbGeAlD
Ruxolitinib—PLK1—lymphoid tissue—pharynx cancer	0.00656	0.0116	CbGeAlD
Ruxolitinib—JAK1—parotid gland—pharynx cancer	0.00653	0.0116	CbGeAlD
Ruxolitinib—PLK3—trachea—pharynx cancer	0.00629	0.0112	CbGeAlD
Ruxolitinib—JAK1—saliva-secreting gland—pharynx cancer	0.00625	0.0111	CbGeAlD
Ruxolitinib—DAPK2—parotid gland—pharynx cancer	0.00623	0.0111	CbGeAlD
Ruxolitinib—BMP2K—neck—pharynx cancer	0.006	0.0107	CbGeAlD
Ruxolitinib—DAPK2—saliva-secreting gland—pharynx cancer	0.00597	0.0106	CbGeAlD
Ruxolitinib—PHKG2—brainstem—pharynx cancer	0.00594	0.0105	CbGeAlD
Ruxolitinib—PRKG2—head—pharynx cancer	0.00589	0.0105	CbGeAlD
Ruxolitinib—CLK2—parotid gland—pharynx cancer	0.0058	0.0103	CbGeAlD
Ruxolitinib—HIPK2—brainstem—pharynx cancer	0.00572	0.0101	CbGeAlD
Ruxolitinib—GRK1—head—pharynx cancer	0.00562	0.00998	CbGeAlD
Ruxolitinib—CLK2—saliva-secreting gland—pharynx cancer	0.00556	0.00986	CbGeAlD
Ruxolitinib—PRKCE—head—pharynx cancer	0.0055	0.00977	CbGeAlD
Ruxolitinib—JAK1—epithelium—pharynx cancer	0.00546	0.00968	CbGeAlD
Ruxolitinib—PLK1—head—pharynx cancer	0.00529	0.00938	CbGeAlD
Ruxolitinib—RPS6KA6—head—pharynx cancer	0.00529	0.00938	CbGeAlD
Ruxolitinib—MAST1—head—pharynx cancer	0.00529	0.00938	CbGeAlD
Ruxolitinib—NUAK2—parotid gland—pharynx cancer	0.00522	0.00926	CbGeAlD
Ruxolitinib—DYRK1A—brainstem—pharynx cancer	0.00515	0.00913	CbGeAlD
Ruxolitinib—BMPR2—brainstem—pharynx cancer	0.00512	0.00909	CbGeAlD
Ruxolitinib—RET—neck—pharynx cancer	0.0051	0.00906	CbGeAlD
Ruxolitinib—DCLK3—head—pharynx cancer	0.00501	0.00889	CbGeAlD
Ruxolitinib—NUAK2—saliva-secreting gland—pharynx cancer	0.005	0.00887	CbGeAlD
Ruxolitinib—JAK1—trachea—pharynx cancer	0.00482	0.00856	CbGeAlD
Ruxolitinib—DCLK1—trachea—pharynx cancer	0.00482	0.00856	CbGeAlD
Ruxolitinib—CAMK1D—trachea—pharynx cancer	0.00471	0.00836	CbGeAlD
Ruxolitinib—ROCK1—epithelium—pharynx cancer	0.0047	0.00834	CbGeAlD
Ruxolitinib—CAMK1—spinal cord—pharynx cancer	0.00464	0.00824	CbGeAlD
Ruxolitinib—DAPK2—trachea—pharynx cancer	0.0046	0.00817	CbGeAlD
Ruxolitinib—CAMK2G—brainstem—pharynx cancer	0.00459	0.00814	CbGeAlD
Ruxolitinib—LRRK2—brainstem—pharynx cancer	0.00455	0.00807	CbGeAlD
Ruxolitinib—PLK3—head—pharynx cancer	0.00441	0.00783	CbGeAlD
Ruxolitinib—MAP3K7—parotid gland—pharynx cancer	0.0044	0.0078	CbGeAlD
Ruxolitinib—TYK2—parotid gland—pharynx cancer	0.00432	0.00766	CbGeAlD
Ruxolitinib—CLK2—trachea—pharynx cancer	0.00429	0.00761	CbGeAlD
Ruxolitinib—LTK—head—pharynx cancer	0.00426	0.00756	CbGeAlD
Ruxolitinib—MKNK2—parotid gland—pharynx cancer	0.00426	0.00756	CbGeAlD
Ruxolitinib—JAK3—lymphoid tissue—pharynx cancer	0.00423	0.0075	CbGeAlD
Ruxolitinib—MAP3K7—saliva-secreting gland—pharynx cancer	0.00421	0.00747	CbGeAlD
Ruxolitinib—JAK1—lymphoid tissue—pharynx cancer	0.0042	0.00746	CbGeAlD
Ruxolitinib—PLK4—lymphoid tissue—pharynx cancer	0.00418	0.00741	CbGeAlD
Ruxolitinib—TYK2—saliva-secreting gland—pharynx cancer	0.00414	0.00734	CbGeAlD
Ruxolitinib—CAMK1—head—pharynx cancer	0.00413	0.00732	CbGeAlD
Ruxolitinib—MKNK2—saliva-secreting gland—pharynx cancer	0.00408	0.00724	CbGeAlD
Ruxolitinib—MARK2—head—pharynx cancer	0.00401	0.00711	CbGeAlD
Ruxolitinib—STK16—lymphoid tissue—pharynx cancer	0.00394	0.007	CbGeAlD
Ruxolitinib—HIPK2—lymphoid tissue—pharynx cancer	0.00392	0.00696	CbGeAlD
Ruxolitinib—NUAK2—trachea—pharynx cancer	0.00386	0.00684	CbGeAlD
Ruxolitinib—PRKCE—lymph node—pharynx cancer	0.00385	0.00684	CbGeAlD
Ruxolitinib—DCLK1—spinal cord—pharynx cancer	0.00381	0.00676	CbGeAlD
Ruxolitinib—JAK1—spinal cord—pharynx cancer	0.00381	0.00676	CbGeAlD
Ruxolitinib—MAP3K3—parotid gland—pharynx cancer	0.00379	0.00672	CbGeAlD
Ruxolitinib—CLK2—lymphoid tissue—pharynx cancer	0.00373	0.00663	CbGeAlD
Ruxolitinib—PLK1—lymph node—pharynx cancer	0.0037	0.00657	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—pharynx cancer	0.0037	0.00657	CbGeAlD
Ruxolitinib—DAPK2—spinal cord—pharynx cancer	0.00363	0.00645	CbGeAlD
Ruxolitinib—MAP3K3—saliva-secreting gland—pharynx cancer	0.00363	0.00643	CbGeAlD
Ruxolitinib—ROCK1—lymphoid tissue—pharynx cancer	0.00362	0.00642	CbGeAlD
Ruxolitinib—MKNK2—epithelium—pharynx cancer	0.00356	0.00632	CbGeAlD
Ruxolitinib—HIPK2—spinal cord—pharynx cancer	0.00356	0.00631	CbGeAlD
Ruxolitinib—DYRK1A—lymphoid tissue—pharynx cancer	0.00353	0.00626	CbGeAlD
Ruxolitinib—BMPR2—lymphoid tissue—pharynx cancer	0.00351	0.00624	CbGeAlD
Ruxolitinib—RET—epithelium—pharynx cancer	0.00347	0.00616	CbGeAlD
Ruxolitinib—TAOK3—parotid gland—pharynx cancer	0.00345	0.00613	CbGeAlD
Ruxolitinib—DAPK3—spinal cord—pharynx cancer	0.00342	0.00606	CbGeAlD
Ruxolitinib—JAK3—head—pharynx cancer	0.00341	0.00605	CbGeAlD
Ruxolitinib—DCLK1—head—pharynx cancer	0.00339	0.00601	CbGeAlD
Ruxolitinib—JAK1—head—pharynx cancer	0.00339	0.00601	CbGeAlD
Ruxolitinib—TAOK3—saliva-secreting gland—pharynx cancer	0.00331	0.00587	CbGeAlD
Ruxolitinib—CAMK1D—head—pharynx cancer	0.0033	0.00586	CbGeAlD
Ruxolitinib—PHKG2—head—pharynx cancer	0.00329	0.00583	CbGeAlD
Ruxolitinib—JAK2—epithelium—pharynx cancer	0.00328	0.00582	CbGeAlD
Ruxolitinib—MAP3K7—trachea—pharynx cancer	0.00325	0.00576	CbGeAlD
Ruxolitinib—TAOK3—brainstem—pharynx cancer	0.00324	0.00575	CbGeAlD
Ruxolitinib—TYK2—trachea—pharynx cancer	0.00319	0.00566	CbGeAlD
Ruxolitinib—STK16—head—pharynx cancer	0.00318	0.00564	CbGeAlD
Ruxolitinib—HIPK2—head—pharynx cancer	0.00316	0.00561	CbGeAlD
Ruxolitinib—MKNK2—trachea—pharynx cancer	0.00315	0.00559	CbGeAlD
Ruxolitinib—MAP3K19—head—pharynx cancer	0.0031	0.0055	CbGeAlD
Ruxolitinib—PLK3—lymph node—pharynx cancer	0.00309	0.00548	CbGeAlD
Ruxolitinib—DAPK3—head—pharynx cancer	0.00304	0.00539	CbGeAlD
Ruxolitinib—CLK2—head—pharynx cancer	0.00301	0.00534	CbGeAlD
Ruxolitinib—LTK—lymph node—pharynx cancer	0.00298	0.0053	CbGeAlD
Ruxolitinib—ROCK1—head—pharynx cancer	0.00292	0.00517	CbGeAlD
Ruxolitinib—JAK2—trachea—pharynx cancer	0.0029	0.00515	CbGeAlD
Ruxolitinib—CAMK1—lymph node—pharynx cancer	0.00289	0.00513	CbGeAlD
Ruxolitinib—MAP3K2—lymphoid tissue—pharynx cancer	0.00286	0.00507	CbGeAlD
Ruxolitinib—CAMK2G—spinal cord—pharynx cancer	0.00285	0.00506	CbGeAlD
Ruxolitinib—BMP2K—spinal cord—pharynx cancer	0.00285	0.00506	CbGeAlD
Ruxolitinib—DYRK1A—head—pharynx cancer	0.00284	0.00505	CbGeAlD
Ruxolitinib—BMPR2—head—pharynx cancer	0.00283	0.00503	CbGeAlD
Ruxolitinib—LRRK2—spinal cord—pharynx cancer	0.00283	0.00502	CbGeAlD
Ruxolitinib—MARK2—lymph node—pharynx cancer	0.00281	0.00498	CbGeAlD
Ruxolitinib—MAP3K3—trachea—pharynx cancer	0.0028	0.00496	CbGeAlD
Ruxolitinib—TYK2—lymphoid tissue—pharynx cancer	0.00278	0.00493	CbGeAlD
Ruxolitinib—MKNK2—lymphoid tissue—pharynx cancer	0.00274	0.00487	CbGeAlD
Ruxolitinib—RET—lymphoid tissue—pharynx cancer	0.00267	0.00475	CbGeAlD
Ruxolitinib—TAOK2—lymph node—pharynx cancer	0.0026	0.00461	CbGeAlD
Ruxolitinib—MAP3K7—spinal cord—pharynx cancer	0.00257	0.00455	CbGeAlD
Ruxolitinib—TAOK3—trachea—pharynx cancer	0.00255	0.00453	CbGeAlD
Ruxolitinib—CAMK2G—head—pharynx cancer	0.00253	0.0045	CbGeAlD
Ruxolitinib—BMP2K—head—pharynx cancer	0.00253	0.0045	CbGeAlD
Ruxolitinib—JAK2—lymphoid tissue—pharynx cancer	0.00253	0.00449	CbGeAlD
Ruxolitinib—TYK2—spinal cord—pharynx cancer	0.00252	0.00447	CbGeAlD
Ruxolitinib—LRRK2—head—pharynx cancer	0.00251	0.00446	CbGeAlD
Ruxolitinib—MKNK2—spinal cord—pharynx cancer	0.00249	0.00441	CbGeAlD
Ruxolitinib—RET—spinal cord—pharynx cancer	0.00242	0.0043	CbGeAlD
Ruxolitinib—JAK3—lymph node—pharynx cancer	0.00239	0.00423	CbGeAlD
Ruxolitinib—DCLK1—lymph node—pharynx cancer	0.00237	0.00421	CbGeAlD
Ruxolitinib—JAK1—lymph node—pharynx cancer	0.00237	0.00421	CbGeAlD
Ruxolitinib—PLK4—lymph node—pharynx cancer	0.00236	0.00418	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—pharynx cancer	0.00231	0.00411	CbGeAlD
Ruxolitinib—MAP3K2—head—pharynx cancer	0.0023	0.00408	CbGeAlD
Ruxolitinib—PHKG2—lymph node—pharynx cancer	0.0023	0.00408	CbGeAlD
Ruxolitinib—JAK2—spinal cord—pharynx cancer	0.00229	0.00407	CbGeAlD
Ruxolitinib—DAPK2—lymph node—pharynx cancer	0.00226	0.00401	CbGeAlD
Ruxolitinib—TYK2—head—pharynx cancer	0.00224	0.00397	CbGeAlD
Ruxolitinib—STK16—lymph node—pharynx cancer	0.00222	0.00395	CbGeAlD
Ruxolitinib—TAOK3—lymphoid tissue—pharynx cancer	0.00222	0.00394	CbGeAlD
Ruxolitinib—HIPK2—lymph node—pharynx cancer	0.00221	0.00393	CbGeAlD
Ruxolitinib—MKNK2—head—pharynx cancer	0.00221	0.00392	CbGeAlD
Ruxolitinib—MAP3K3—spinal cord—pharynx cancer	0.00221	0.00392	CbGeAlD
Ruxolitinib—RET—head—pharynx cancer	0.00215	0.00382	CbGeAlD
Ruxolitinib—DAPK3—lymph node—pharynx cancer	0.00213	0.00377	CbGeAlD
Ruxolitinib—CLK2—lymph node—pharynx cancer	0.00211	0.00374	CbGeAlD
Ruxolitinib—JAK2—head—pharynx cancer	0.00204	0.00361	CbGeAlD
Ruxolitinib—TAOK3—spinal cord—pharynx cancer	0.00201	0.00357	CbGeAlD
Ruxolitinib—DYRK1A—lymph node—pharynx cancer	0.00199	0.00353	CbGeAlD
Ruxolitinib—BMPR2—lymph node—pharynx cancer	0.00198	0.00352	CbGeAlD
Ruxolitinib—MAP3K3—head—pharynx cancer	0.00196	0.00348	CbGeAlD
Ruxolitinib—NUAK2—lymph node—pharynx cancer	0.0019	0.00336	CbGeAlD
Ruxolitinib—TAOK3—head—pharynx cancer	0.00179	0.00318	CbGeAlD
Ruxolitinib—BMP2K—lymph node—pharynx cancer	0.00177	0.00315	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—pharynx cancer	0.00177	0.00315	CbGeAlD
Ruxolitinib—LRRK2—lymph node—pharynx cancer	0.00176	0.00312	CbGeAlD
Ruxolitinib—MAP3K2—lymph node—pharynx cancer	0.00161	0.00286	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—pharynx cancer	0.0016	0.00283	CbGeAlD
Ruxolitinib—TYK2—lymph node—pharynx cancer	0.00157	0.00278	CbGeAlD
Ruxolitinib—MKNK2—lymph node—pharynx cancer	0.00155	0.00275	CbGeAlD
Ruxolitinib—IRAK1—lymph node—pharynx cancer	0.00155	0.00275	CbGeAlD
Ruxolitinib—RET—lymph node—pharynx cancer	0.00151	0.00268	CbGeAlD
Ruxolitinib—JAK2—lymph node—pharynx cancer	0.00143	0.00253	CbGeAlD
Ruxolitinib—MAP3K3—lymph node—pharynx cancer	0.00137	0.00244	CbGeAlD
Ruxolitinib—TAOK3—lymph node—pharynx cancer	0.00125	0.00222	CbGeAlD
Ruxolitinib—BMPR2—Integrated Breast Cancer Pathway—EGFR—pharynx cancer	0.00107	0.00244	CbGpPWpGaD
Ruxolitinib—HIPK2—Integrated Breast Cancer Pathway—TP53—pharynx cancer	0.00105	0.00241	CbGpPWpGaD
Ruxolitinib—JAK2—GRB2 events in ERBB2 signaling—EGFR—pharynx cancer	0.00103	0.00235	CbGpPWpGaD
Ruxolitinib—JAK2—SHC1 events in ERBB2 signaling—EGFR—pharynx cancer	0.000974	0.00223	CbGpPWpGaD
Ruxolitinib—PLK1—Integrated Breast Cancer Pathway—CCND1—pharynx cancer	0.000969	0.00222	CbGpPWpGaD
Ruxolitinib—LRRK2—MAPK Signaling Pathway—TP53—pharynx cancer	0.000968	0.00222	CbGpPWpGaD
Ruxolitinib—MAP3K2—ErbB1 downstream signaling—EGFR—pharynx cancer	0.000964	0.00221	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—ADH1B—pharynx cancer	0.000964	0.00221	CbGpPWpGaD
Ruxolitinib—JAK3—Oncostatin M Signaling Pathway—TP53—pharynx cancer	0.000964	0.00221	CbGpPWpGaD
Ruxolitinib—ROCK1—Androgen receptor signaling pathway—CCND1—pharynx cancer	0.000963	0.00221	CbGpPWpGaD
Ruxolitinib—ROCK1—AGE/RAGE pathway—EGFR—pharynx cancer	0.000959	0.0022	CbGpPWpGaD
Ruxolitinib—PLK4—Retinoblastoma (RB) in Cancer—TP53—pharynx cancer	0.000926	0.00212	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—B4GALT5—pharynx cancer	0.000921	0.00211	CbGpPWpGaD
Ruxolitinib—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—pharynx cancer	0.000902	0.00207	CbGpPWpGaD
Ruxolitinib—MAP3K7—B Cell Activation—CD79A—pharynx cancer	0.000901	0.00206	CbGpPWpGaD
Ruxolitinib—BMPR2—Integrated Breast Cancer Pathway—TP53—pharynx cancer	0.000896	0.00205	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—TP53—pharynx cancer	0.000874	0.002	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling events mediated by PTP1B—EGFR—pharynx cancer	0.000871	0.002	CbGpPWpGaD
Ruxolitinib—JAK1—Integrated Breast Cancer Pathway—CDH1—pharynx cancer	0.00086	0.00197	CbGpPWpGaD
Ruxolitinib—PRKG2—Circadian rythm related genes—TP53—pharynx cancer	0.000838	0.00192	CbGpPWpGaD
Ruxolitinib—JAK1—Oncostatin M Signaling Pathway—TP53—pharynx cancer	0.000829	0.0019	CbGpPWpGaD
Ruxolitinib—ROCK1—Apoptosis—CDH1—pharynx cancer	0.000829	0.0019	CbGpPWpGaD
Ruxolitinib—PLK1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.000803	0.00184	CbGpPWpGaD
Ruxolitinib—PRKCE—Wnt Signaling Pathway and Pluripotency—TP53—pharynx cancer	0.000796	0.00182	CbGpPWpGaD
Ruxolitinib—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—pharynx cancer	0.000791	0.00181	CbGpPWpGaD
Ruxolitinib—PLK1—Integrated Breast Cancer Pathway—EGFR—pharynx cancer	0.00076	0.00174	CbGpPWpGaD
Ruxolitinib—ROCK1—Androgen receptor signaling pathway—EGFR—pharynx cancer	0.000755	0.00173	CbGpPWpGaD
Ruxolitinib—JAK2—Notch Signaling Pathway—CCND1—pharynx cancer	0.000741	0.0017	CbGpPWpGaD
Ruxolitinib—MAP3K7—C-MYB transcription factor network—CCND1—pharynx cancer	0.000734	0.00168	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—B4GALT5—pharynx cancer	0.000714	0.00164	CbGpPWpGaD
Ruxolitinib—DYRK1A—Circadian rythm related genes—TP53—pharynx cancer	0.000713	0.00163	CbGpPWpGaD
Ruxolitinib—ROCK1—TGF-beta Signaling Pathway—CCND1—pharynx cancer	0.000702	0.00161	CbGpPWpGaD
Ruxolitinib—PRKCE—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.0007	0.0016	CbGpPWpGaD
Ruxolitinib—MAP3K2—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000681	0.00156	CbGpPWpGaD
Ruxolitinib—MAP3K2—MAPK Signaling Pathway—EGFR—pharynx cancer	0.000662	0.00152	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling events mediated by PTP1B—EGFR—pharynx cancer	0.00066	0.00151	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Axon guidance—EGFR—pharynx cancer	0.00066	0.00151	CbGpPWpGaD
Ruxolitinib—PRKCE—Downstream signal transduction—EGFR—pharynx cancer	0.000658	0.00151	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by FGFR—EGFR—pharynx cancer	0.000655	0.0015	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by ERBB2—EGFR—pharynx cancer	0.000652	0.00149	CbGpPWpGaD
Ruxolitinib—PRKCE—DAP12 signaling—EGFR—pharynx cancer	0.000649	0.00149	CbGpPWpGaD
Ruxolitinib—JAK1—Integrated Breast Cancer Pathway—CCND1—pharynx cancer	0.000641	0.00147	CbGpPWpGaD
Ruxolitinib—PLK1—Integrated Breast Cancer Pathway—TP53—pharynx cancer	0.000638	0.00146	CbGpPWpGaD
Ruxolitinib—PLK1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.00063	0.00144	CbGpPWpGaD
Ruxolitinib—MAP3K7—Wnt Signaling Pathway and Pluripotency—CCND1—pharynx cancer	0.000628	0.00144	CbGpPWpGaD
Ruxolitinib—JAK2—RMTs methylate histone arginines—CCND1—pharynx cancer	0.000628	0.00144	CbGpPWpGaD
Ruxolitinib—JAK2—Leptin signaling pathway—CCND1—pharynx cancer	0.000628	0.00144	CbGpPWpGaD
Ruxolitinib—TYK2—Oncostatin M Signaling Pathway—TP53—pharynx cancer	0.000612	0.0014	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by FGFR in disease—EGFR—pharynx cancer	0.00061	0.0014	CbGpPWpGaD
Ruxolitinib—PRKCE—DAP12 interactions—EGFR—pharynx cancer	0.00061	0.0014	CbGpPWpGaD
Ruxolitinib—JAK2—SHP2 signaling—EGFR—pharynx cancer	0.000605	0.00139	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by EGFR—EGFR—pharynx cancer	0.000605	0.00139	CbGpPWpGaD
Ruxolitinib—IRAK1—p75(NTR)-mediated signaling—TP53—pharynx cancer	0.000601	0.00138	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000599	0.00137	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by PDGF—EGFR—pharynx cancer	0.000597	0.00137	CbGpPWpGaD
Ruxolitinib—MAP3K7—DNA Damage Response (only ATM dependent)—CCND1—pharynx cancer	0.000596	0.00137	CbGpPWpGaD
Ruxolitinib—MAP3K3—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000586	0.00134	CbGpPWpGaD
Ruxolitinib—MAP3K2—MAPK Signaling Pathway—TP53—pharynx cancer	0.000556	0.00127	CbGpPWpGaD
Ruxolitinib—JAK2—AGE/RAGE pathway—EGFR—pharynx cancer	0.000546	0.00125	CbGpPWpGaD
Ruxolitinib—DYRK1A—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000546	0.00125	CbGpPWpGaD
Ruxolitinib—PRKCE—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.00054	0.00124	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by SCF-KIT—EGFR—pharynx cancer	0.000531	0.00122	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—CNDP2—pharynx cancer	0.00053	0.00121	CbGpPWpGaD
Ruxolitinib—PLK1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000529	0.00121	CbGpPWpGaD
Ruxolitinib—ROCK1—Focal Adhesion—CCND1—pharynx cancer	0.000525	0.0012	CbGpPWpGaD
Ruxolitinib—PRKCE—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pharynx cancer	0.000522	0.0012	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—B4GALT5—pharynx cancer	0.000519	0.00119	CbGpPWpGaD
Ruxolitinib—MAP3K7—TGF-beta Signaling Pathway—CCND1—pharynx cancer	0.000511	0.00117	CbGpPWpGaD
Ruxolitinib—JAK1—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.000508	0.00116	CbGpPWpGaD
Ruxolitinib—JAK1—Integrated Breast Cancer Pathway—EGFR—pharynx cancer	0.000503	0.00115	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by ERBB4—EGFR—pharynx cancer	0.0005	0.00115	CbGpPWpGaD
Ruxolitinib—ROCK1—Regulation of Actin Cytoskeleton—EGFR—pharynx cancer	0.0005	0.00115	CbGpPWpGaD
Ruxolitinib—DYRK1A—Cell Cycle—CCND1—pharynx cancer	0.000488	0.00112	CbGpPWpGaD
Ruxolitinib—IRAK1—Apoptosis Modulation and Signaling—TP53—pharynx cancer	0.000482	0.0011	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—ADH7—pharynx cancer	0.000479	0.0011	CbGpPWpGaD
Ruxolitinib—JAK1—Downstream signal transduction—EGFR—pharynx cancer	0.000478	0.00109	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by FGFR—EGFR—pharynx cancer	0.000476	0.00109	CbGpPWpGaD
Ruxolitinib—JAK1—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000476	0.00109	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by ERBB2—EGFR—pharynx cancer	0.000473	0.00108	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Developmental Biology—EGFR—pharynx cancer	0.000471	0.00108	CbGpPWpGaD
Ruxolitinib—JAK1—DAP12 signaling—EGFR—pharynx cancer	0.000471	0.00108	CbGpPWpGaD
Ruxolitinib—ROCK1—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000468	0.00107	CbGpPWpGaD
Ruxolitinib—JAK2—Oncostatin M Signaling Pathway—TP53—pharynx cancer	0.000464	0.00106	CbGpPWpGaD
Ruxolitinib—ROCK1—TGF-beta Signaling Pathway—TP53—pharynx cancer	0.000463	0.00106	CbGpPWpGaD
Ruxolitinib—JAK1—DAP12 interactions—EGFR—pharynx cancer	0.000443	0.00101	CbGpPWpGaD
Ruxolitinib—JAK1—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000443	0.00101	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000443	0.00101	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by EGFR—EGFR—pharynx cancer	0.000439	0.00101	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000435	0.000997	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by PDGF—EGFR—pharynx cancer	0.000433	0.000993	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CD79A—pharynx cancer	0.000424	0.000971	CbGpPWpGaD
Ruxolitinib—JAK1—Integrated Breast Cancer Pathway—TP53—pharynx cancer	0.000422	0.000968	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—ADH1B—pharynx cancer	0.00042	0.000963	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by NGF—EGFR—pharynx cancer	0.000416	0.000952	CbGpPWpGaD
Ruxolitinib—MAP3K7—Wnt Signaling Pathway and Pluripotency—TP53—pharynx cancer	0.000414	0.000948	CbGpPWpGaD
Ruxolitinib—ROCK1—Focal Adhesion—EGFR—pharynx cancer	0.000412	0.000943	CbGpPWpGaD
Ruxolitinib—ROCK1—Apoptosis—TP53—pharynx cancer	0.000407	0.000932	CbGpPWpGaD
Ruxolitinib—PRKG2—Hemostasis—TP53—pharynx cancer	0.000401	0.000918	CbGpPWpGaD
Ruxolitinib—MAP3K7—DNA Damage Response (only ATM dependent)—TP53—pharynx cancer	0.000393	0.000899	CbGpPWpGaD
Ruxolitinib—JAK1—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000392	0.000899	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by SCF-KIT—EGFR—pharynx cancer	0.000392	0.000899	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000389	0.000891	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD79A—pharynx cancer	0.000388	0.000889	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—B4GALT5—pharynx cancer	0.000383	0.000877	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CD79A—pharynx cancer	0.000379	0.000869	CbGpPWpGaD
Ruxolitinib—JAK1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pharynx cancer	0.000379	0.000869	CbGpPWpGaD
Ruxolitinib—TYK2—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.000375	0.00086	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by ERBB4—EGFR—pharynx cancer	0.000369	0.000846	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD79A—pharynx cancer	0.000363	0.000832	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000363	0.000831	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD79A—pharynx cancer	0.000358	0.00082	CbGpPWpGaD
Ruxolitinib—TYK2—Downstream signal transduction—EGFR—pharynx cancer	0.000353	0.000808	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by FGFR—EGFR—pharynx cancer	0.000351	0.000804	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by ERBB2—EGFR—pharynx cancer	0.000349	0.0008	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—CCND1—pharynx cancer	0.000348	0.000796	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 signaling—EGFR—pharynx cancer	0.000348	0.000796	CbGpPWpGaD
Ruxolitinib—CAMK2G—Cellular responses to stress—TP53—pharynx cancer	0.000341	0.000781	CbGpPWpGaD
Ruxolitinib—MAP3K7—TGF-beta Signaling Pathway—TP53—pharynx cancer	0.000337	0.000772	CbGpPWpGaD
Ruxolitinib—MAP3K7—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000332	0.000761	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—EGFR—pharynx cancer	0.000331	0.000758	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 interactions—EGFR—pharynx cancer	0.000327	0.000749	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000327	0.000749	CbGpPWpGaD
Ruxolitinib—TYK2—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000327	0.000749	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—CCND1—pharynx cancer	0.000324	0.000743	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR—EGFR—pharynx cancer	0.000324	0.000743	CbGpPWpGaD
Ruxolitinib—DYRK1A—Cell Cycle—TP53—pharynx cancer	0.000321	0.000736	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000321	0.000736	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by PDGF—EGFR—pharynx cancer	0.00032	0.000733	CbGpPWpGaD
Ruxolitinib—MAP3K7—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000317	0.000727	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD79A—pharynx cancer	0.000308	0.000705	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by NGF—EGFR—pharynx cancer	0.000302	0.000691	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by SCF-KIT—EGFR—pharynx cancer	0.000297	0.000681	CbGpPWpGaD
Ruxolitinib—MAP3K7—B Cell Activation—EGFR—pharynx cancer	0.000294	0.000673	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—B4GALT5—pharynx cancer	0.00029	0.000665	CbGpPWpGaD
Ruxolitinib—TYK2—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.00029	0.000664	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.000284	0.000652	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB4—EGFR—pharynx cancer	0.00028	0.000641	CbGpPWpGaD
Ruxolitinib—TYK2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pharynx cancer	0.00028	0.000641	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—TP53—pharynx cancer	0.000278	0.000636	CbGpPWpGaD
Ruxolitinib—JAK1—Axon guidance—EGFR—pharynx cancer	0.000273	0.000626	CbGpPWpGaD
Ruxolitinib—ROCK1—Axon guidance—EGFR—pharynx cancer	0.000269	0.000615	CbGpPWpGaD
Ruxolitinib—JAK2—Chromatin modifying enzymes—CCND1—pharynx cancer	0.000268	0.000615	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signal transduction—EGFR—pharynx cancer	0.000267	0.000613	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR—EGFR—pharynx cancer	0.000266	0.00061	CbGpPWpGaD
Ruxolitinib—JAK2—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000266	0.00061	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB2—EGFR—pharynx cancer	0.000265	0.000607	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 signaling—EGFR—pharynx cancer	0.000263	0.000604	CbGpPWpGaD
Ruxolitinib—JAK2—Factors involved in megakaryocyte development and platelet production—TP53—pharynx cancer	0.000257	0.000589	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000248	0.000568	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—EGFR—pharynx cancer	0.000248	0.000568	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000248	0.000568	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—EGFR—pharynx cancer	0.000246	0.000563	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000243	0.000558	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—EGFR—pharynx cancer	0.000242	0.000555	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—EGFR—pharynx cancer	0.000237	0.000543	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CDH1—pharynx cancer	0.000236	0.000541	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD79A—pharynx cancer	0.000234	0.000536	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—EGFR—pharynx cancer	0.000229	0.000526	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—TP53—pharynx cancer	0.000229	0.000525	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD79A—pharynx cancer	0.000227	0.00052	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—EGFR—pharynx cancer	0.000223	0.00051	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—TP53—pharynx cancer	0.000221	0.000507	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD79A—pharynx cancer	0.00022	0.000505	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.00022	0.000503	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—EGFR—pharynx cancer	0.000217	0.000497	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CDH1—pharynx cancer	0.000216	0.000495	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—TP53—pharynx cancer	0.000214	0.000489	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pharynx cancer	0.000212	0.000486	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CDH1—pharynx cancer	0.000211	0.000484	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—CCND1—pharynx cancer	0.000206	0.000472	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CDH1—pharynx cancer	0.000202	0.000464	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—EGFR—pharynx cancer	0.000202	0.000462	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CDH1—pharynx cancer	0.000199	0.000457	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—EGFR—pharynx cancer	0.000196	0.00045	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—EGFR—pharynx cancer	0.000195	0.000447	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—CCND1—pharynx cancer	0.000194	0.000444	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—EGFR—pharynx cancer	0.000192	0.000439	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—TP53—pharynx cancer	0.000187	0.000427	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CCND1—pharynx cancer	0.000175	0.000402	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD79A—pharynx cancer	0.000172	0.000394	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—EGFR—pharynx cancer	0.000172	0.000394	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CDH1—pharynx cancer	0.000171	0.000393	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—EGFR—pharynx cancer	0.000169	0.000387	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—EGFR—pharynx cancer	0.000162	0.000371	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—pharynx cancer	0.000161	0.000368	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—EGFR—pharynx cancer	0.000153	0.00035	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—EGFR—pharynx cancer	0.000152	0.000348	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—EGFR—pharynx cancer	0.000151	0.000346	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—EGFR—pharynx cancer	0.000144	0.00033	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EGFR—pharynx cancer	0.000138	0.000316	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EGFR—pharynx cancer	0.000138	0.000315	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—pharynx cancer	0.000136	0.000311	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EGFR—pharynx cancer	0.000131	0.0003	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CDH1—pharynx cancer	0.00013	0.000299	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—pharynx cancer	0.000128	0.000292	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—EGFR—pharynx cancer	0.000128	0.000292	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EGFR—pharynx cancer	0.000127	0.000292	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EGFR—pharynx cancer	0.000127	0.000291	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CDH1—pharynx cancer	0.000127	0.00029	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EGFR—pharynx cancer	0.000126	0.00029	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EGFR—pharynx cancer	0.000124	0.000283	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EGFR—pharynx cancer	0.000123	0.000282	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CDH1—pharynx cancer	0.000123	0.000281	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—EGFR—pharynx cancer	0.000118	0.000271	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EGFR—pharynx cancer	0.000117	0.000267	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—pharynx cancer	0.000115	0.000265	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CCND1—pharynx cancer	0.000114	0.000261	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—EGFR—pharynx cancer	0.00011	0.000251	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EGFR—pharynx cancer	0.000109	0.00025	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EGFR—pharynx cancer	0.000108	0.000247	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—pharynx cancer	0.0001	0.00023	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—pharynx cancer	9.63e-05	0.000221	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCND1—pharynx cancer	9.6e-05	0.00022	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDH1—pharynx cancer	9.59e-05	0.00022	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—pharynx cancer	9.26e-05	0.000212	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CNDP2—pharynx cancer	9.06e-05	0.000208	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—pharynx cancer	8.98e-05	0.000206	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—pharynx cancer	8.93e-05	0.000205	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—pharynx cancer	8.26e-05	0.000189	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADH7—pharynx cancer	8.19e-05	0.000188	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—pharynx cancer	8.13e-05	0.000186	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—pharynx cancer	8.1e-05	0.000186	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—pharynx cancer	7.62e-05	0.000175	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—pharynx cancer	7.53e-05	0.000173	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—pharynx cancer	7.5e-05	0.000172	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—pharynx cancer	7.4e-05	0.00017	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADH1B—pharynx cancer	7.19e-05	0.000165	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—pharynx cancer	7.18e-05	0.000164	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—B4GALT5—pharynx cancer	6.87e-05	0.000157	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—pharynx cancer	6.83e-05	0.000157	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—pharynx cancer	6.48e-05	0.000148	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—pharynx cancer	6.38e-05	0.000146	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—pharynx cancer	6.33e-05	0.000145	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—pharynx cancer	6.28e-05	0.000144	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—pharynx cancer	6.14e-05	0.000141	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—pharynx cancer	6.1e-05	0.00014	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—pharynx cancer	5.92e-05	0.000136	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—pharynx cancer	5.61e-05	0.000128	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—pharynx cancer	5.44e-05	0.000125	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—pharynx cancer	5.35e-05	0.000123	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—pharynx cancer	5.18e-05	0.000119	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—pharynx cancer	4.93e-05	0.000113	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—pharynx cancer	4.79e-05	0.00011	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—pharynx cancer	4.64e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—pharynx cancer	4.62e-05	0.000106	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—pharynx cancer	4.14e-05	9.48e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—pharynx cancer	4.02e-05	9.2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—pharynx cancer	3.9e-05	8.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—pharynx cancer	3.63e-05	8.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—pharynx cancer	3.04e-05	6.98e-05	CbGpPWpGaD
